Spero Biopharma
Biopharmaceutical company focused on developing therapeutic candidates for chronic diseases. The company advances clinical-stage and preclinical compounds targeting neurodegeneration (mild cognitive impairment) and metabolic liver disease (NASH). Founder is an academic inventor with a history in drug discovery. The site emphasizes completed Phase II clinical work for a neuroprotective candidate and preclinical readiness for a NASH candidate.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage therapeutic candidate for mild cognitive impairment (MCI)
Neuroprotective therapy that has completed a multinational Phase II trial and is supported by preclinical and clinical data demonstrating reduction of microglial activation and inhibition of pro-inflammatory cytokines.
Preclinical therapeutic candidate for NASH
Candidate supported by a substantial preclinical data package described as ready to proceed to Phase I clinical evaluation.
Clinical-stage therapeutic candidate for mild cognitive impairment (MCI)
Neuroprotective therapy that has completed a multinational Phase II trial and is supported by preclinical and clinical data demonstrating reduction of microglial activation and inhibition of pro-inflammatory cytokines.
Preclinical therapeutic candidate for NASH
Candidate supported by a substantial preclinical data package described as ready to proceed to Phase I clinical evaluation.
Expertise Areas
- Clinical trial management
- Translational pharmacology
- Neuroprotective therapeutics
- NASH (non-alcoholic steatohepatitis) drug development
Key Technologies
- Preclinical pharmacology
- Mechanism-of-action assays (microglial activation, cytokine profiling)
- Multinational Phase II clinical trial execution
- IND-enabling study packages